Topics
PRD Therapeutics Initiates First-in-Human Clinical Trial of SOAT2-Selective Inhibitor ‘PRD001’ — Axcelead DDP Provides Comprehensive Non-Clinical Development Support —
2025.07.15
PRD Therapeutics, Inc. (“PRD Therapeutics”), a clinical stage company focused on developing novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), announced on June 28 that it has initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2-selective inhibitor.
Axcelead DDP supports startups facing the challenge of drug development with limited resources by providing solutions for fast and efficient discovery. In this project, we supported the planning and execution of the non-clinical study package required to initiate the FIH clinical trial of PRD Therapeutics‘ PRD001.
Leveraging our extensive experience and deep expertise in drug discovery, Axcelead DDP provided comprehensive support through close collaboration among relevant departments, helping to address various challenges in the non-clinical stage and contributing to the achievement of the key milestone.
On the occasion of the FIH clinical trial initiation, Dr. Kanji Hosoda, President and CEO of PRD Therapeutics, commented:
“Since our establishment, we have worked closely with Axcelead DDP on the research and development of PRD001. Thanks to the high level of expertise and seamless collaboration with project team members and managers specializing in safety, pharmacokinetics, physicochemical properties, and synthesis, we were able to proceed with development quickly and efficiently. We are very pleased that we have now successfully initiated the FIH clinical trial.”
Axcelead DDP is a drug discovery solution provider that utilizes a platform originally inherited from a pharmaceutical company to address challenges encountered throughout the drug discovery process. As a trusted partner to all those engaged in drug discovery, we remain committed to contributing to the creation of innovative medicines.